Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05414500 · ClinicalTrials.gov registry record · Phase 1
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
A Phase 1 study of Cutaneous T Cell Lymphoma and Mycosis Fungoides, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05414500 is a Phase 1 study of Cutaneous T Cell Lymphoma and Mycosis Fungoides that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 10 participants, below the 67-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05414500, a Phase 1 study of Cutaneous T Cell Lymphoma and Mycosis Fungoides, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label, single center, non-randomized dose de-escalation phase I study of combination of BV and Mogamulizumab. The primary objective of the study is to assess the safety and tolerability of the combination. The primary objective is also to explore safe dose of combination for future expansion.
Conditions Studied
Interventions
- DRUG Brentuximab vedotin
- DRUG Mogamulizumab
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05414500
The ClinicalTrials.gov registry entry for NCT05414500 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 67-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (85% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cutaneous T Cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Brentuximab vedotin is the first listed.
NCT05414500 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT05414500 about?
NCT05414500 is a clinical study titled "Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides". This is an open label, single center, non-randomized dose de-escalation phase I study of combination of BV and Mogamulizumab. The primary objective of the study is to assess the safety and tolerability of the combination. The primary objective is also to explore safe dose of combination for future ...
What is the current status of trial NCT05414500?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2023-05-01. Estimated completion is 2026-07-31.
What conditions does trial NCT05414500 study?
This clinical trial studies the following conditions: Cutaneous T Cell Lymphoma, Mycosis Fungoides.
What interventions are being tested in trial NCT05414500?
The interventions under investigation include: Brentuximab vedotin (DRUG), Mogamulizumab (DRUG).
Who is sponsoring clinical trial NCT05414500?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05414500 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous T Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
RECRUITING · Phase 1
-
A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
RECRUITING · Phase 1
-
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
RECRUITING · Phase 1
-
Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)
COMPLETED · Phase 1
-
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.